文献速递胸部肿瘤

肺腺癌中的药物敏感性FGFR3突变

Drug-sensitive FGFR3 mutations in lung adenocarcinoma.
PubMed 文献 · Ann Oncol · 2017-01-01

研究对45例印度原发肺腺癌肿瘤进行676个扩增子测序,并在363例额外肿瘤中对49个突变进行基因分型。发现FGFR3突变存在于363例中的20例(5.5%),这些突变具有组成性活性和致癌性,抑制FGFR3激酶活性可抑制转化和异种移植瘤生长。FGFR3突变在较年轻患者中显著更高,并显示总生存改善趋势。

要点

  • FGFR3突变在363例印度肺腺癌患者中占20例(5.5%)。
  • FGFR3突变在NIH/3T3细胞和NOD/SCID小鼠异种移植模型中具有组成性活性和致癌性。
  • 抑制FGFR3激酶活性可抑制FGFR3过表达细胞的转化和FGFR3驱动肿瘤的生长。

核心结论

  • 研究呈现了印度肺癌基因组中首个可操作突变谱,这些发现提示FGFR3作为肺腺癌的新治疗靶点。

研究设计与样本

  • 对45例原发肺腺癌肿瘤使用RainDance癌症panel测序676个扩增子,平均覆盖度1500×。
  • 在另外363例原发肺腺癌肿瘤中使用质谱对23个基因的49个突变进行基因分型。
  • 使用过表达突变型和野生型FGFR3构建体的NIH/3T3细胞,通过体外和异种移植小鼠模型评估锚定非依赖性生长、组成性激活、肿瘤形成和FGFR抑制剂敏感性。

主要发现

  • FGFR3突变存在于363例患者中的20例(5.5%)。
  • FGFR3突变在NIH/3T3细胞中异位表达时具有组成性活性和致癌性,并在NOD/SCID小鼠异种移植模型中验证。
  • 抑制FGFR3激酶活性可抑制过表达FGFR3构建体的NIH/3T3细胞转化和异种移植模型中FGFR3驱动肿瘤的生长。
  • 小鼠肿瘤体积减小伴随磷酸化ERK量减少,验证了体外发现。
  • FGFR3突变在一部分较年轻患者中显著更高,与缺乏可操作改变或携带KRAS突变的患者相比显示总生存改善趋势。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lung cancer is the leading cause of cancer-related deaths across the world. In this study, we present therapeutically relevant genetic alterations in lung adenocarcinoma of Indian origin. MATERIALS AND METHODS: Forty-five primary lung adenocarcinoma tumors were sequenced for 676 amplicons using RainDance cancer panel at an average coverage of 1500 × (reads per million mapped reads). To validate the findings, 49 mutations across 23 genes were genotyped in an additional set of 363 primary lung adenocarcinoma tumors using mass spectrometry. NIH/3T3 cells over expressing mutant and wild-type FGFR3 constructs were characterized for anchorage independent growth, constitutive activation, tumor formation and sensitivity to FGFR inhibitors using in vitro and xenograft mouse models. RESULTS: We present the first spectrum of actionable alterations in lung adenocarcinoma tumors of Indian origin, and shows that mutations of FGFR3 are present in 20 of 363 (5.5%) patients. These FGFR3 mutations are constitutively active and oncogenic when ectopically expressed in NIH/3T3 cells and using a xenograft model in NOD/SCID mice. Inhibition of FGFR3 kinase activity inhibits transformation of NIH/3T3 overexpressing FGFR3 constructs and growth of tumors driven by FGFR3 in the xenograft models. The reduction in tumor size in the mouse is paralleled by a reduction in the amounts of phospho-ERK, validating the in vitro findings. Interestingly, the FGFR3 mutations are significantly higher in a proportion of younger patients and show a trend toward better overall survival, compared with patients lacking actionable alterations or those harboring KRAS mutations. CONCLUSION: We present the first actionable mutation spectrum in Indian lung cancer genome. These findings implicate FGFR3 as a novel therapeutic in lung adenocarcinoma.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Chandrani P, Prabhash K, Prasad R, et al. Drug-sensitive FGFR3 mutations in lung adenocarcinoma. Ann Oncol. 2017. PMID: 27998968. doi:10.1093/annonc/mdw636

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。